Vasodilatadores pulmonares Parte 1

Clara Patricia García, MD.

Resumen


Los vasodilatadores pulmonares actualmente son fármacos empleados en el tratamiento de pacientes con hipertensión arterial pulmonar, los cuales se han introducido en los últimos años y muchos de ellos ya están disponibles en Colombia para su uso. Sin embargo, el advenimiento de estas terapias amerita un conocimiento más profundo de sus acciones, potenciales interacciones, mecanismos de acción y efectos adversos, así como de los beneficios demostrados en los diversos estudios clínicos que permiten que el médico haga una selección más adecuada para cada individuo que padece esta enfermedad según su grupo, comorbilidades y clase funcional, al igual que para educar tanto al médico como al paciente acerca del reconocimiento de sus potenciales eventos adversos.


Palabras clave


hipertensión pulmonar; vasodilatadores; prostaciclina; endotelina; guanilato ciclasa

Texto completo:

PDF

Referencias


Darius H, Hossmann V, Schrör K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study. Klin Wochenschr. 1986;64:545-51.

J ohnson EJ, Mackie IJ, Machin SJ, Brozović B. Preservation of platelet function in cryopreserved platelet concentrates with prostacyclin. Clin Lab Haemat. 1984;6:141-4.

Gomberg M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur Respir J. 2008;31:891-901.

Monografía Ventavis®

Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Circulation 1982;66:334-8.

McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-82.

Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-78.

Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seeger W. Aerosolised prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820-4.

Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med. 2000;132:435-43.

Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.

Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003;124:1294-304.

McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-63.

Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26:1895-1902.

Wilkens H et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-22.

Ghofrani HA, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 41:158-164.

Galie N, Humbert M, Vachie´ry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, doubleblind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-1502.

Ono F, Nagaya N, Okumura H, ShimizuY, Kyotani S, Nakanishi N, et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest. 2003;123:1583-88.

Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800-4.

Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129:683-688.

Voswinckel R, Enke B, Reichenberger F, et al. Favourable effects of inhaled treprostinil in severe pulmonary hypertension. J Am Coll Cardiol. 2006;48:1672-1681.

Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hipertensión therapy. Eur Respir Rev. 2009;18:35-41.

Ghofrani HA, Weimann G, Frey R, et al. BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacology. 2007;7:S8.

Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33:785-92.

Ghofrani HA, Weimann G, Frey R, et al. BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacology. 2007;7:S8.

Archer S, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension, N Engl J Med. 2009;361:1864-71.

Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol. 2002;53:13S-20S.

Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko R, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61:280-288.

Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.

Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2007;30:922-7.

Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-903.

Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.

Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158-64.

Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005;96: 1334-6.

Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521-30.

Archer S, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864-71.

Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis. Clinical Research Network. N Engl J Med. 2010;363:620-628.

GlaxoSmithKline. Ficha Técnica Flolan®. Marzo 2007.




DOI: http://dx.doi.org/10.30789/rcneumologia.v25.n2.2013.119

Métricas de artículo

Vistas de resumen
636




Cargando métricas ...

Enlaces refback

  • No hay ningún enlace refback.


Asociación Colombiana de Neumología y Cirugía de Tórax.
Dirección: Carrera 7 Bis # 123-52 Of. 202, Teléfono: 57(1)3222335 - Bogotá - Colombia.
Sistema OJS - Metabiblioteca |